Recent News

• 02.24.2025 - NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
• 02.24.2025 - NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
• 02.24.2025 - NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
• 02.04.2025 - NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
• 02.04.2025 - NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
• 02.04.2025 - NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
• 12.19.2024 - NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
• 12.19.2024 - NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
• 12.19.2024 - NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
• 07.17.2024 - NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

Recent Filings

• 04.15.2024 - 15-12G Securities registration termination [Section 12(g)]
• 04.08.2024 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2024 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2024 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2024 - EFFECT Notice of Effectiveness
• 04.08.2024 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2024 - 4 Statement of changes in beneficial ownership of securities